Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents with Tourette's Disorder

Study identifier:D3032C00001

ClinicalTrials.gov identifier:NCT01904773

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents with Tourette's Disorder

Medical condition

Tourette Syndrome

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD5213 and placebo

Sex

All

Actual Enrollment

29

Study type

Interventional

Age

12 Years - 17 Years

Date

Study Start Date: 01 Aug 2013
Primary Completion Date: 01 Feb 2015
Study Completion Date: 01 Feb 2015

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria